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Abstract
The goals of this trial are to determine the efficacy and safety of two treatments for women 
experiencing fecal incontinence. First, we aim to compare the use of loperamide to placebo and 
second, to compare the use of anal sphincter exercises with biofeedback to usual care. The primary 
outcome is the change from baseline in the St. Mark's (Vaizey) Score 24 weeks after treatment 
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initiation. As a Pelvic Floor Disorders Network (PFDN) trial, subjects are enrolling from eight 
PFDN clinical centers across the United States. A centralized data coordinating center supervises 
data collection and analysis. These two first-line treatments for fecal incontinence are being 
investigated simultaneously using a two-by-two randomized factorial design: a medication 
intervention (loperamide versus placebo) and a pelvic floor strength and sensory training 
intervention (anal sphincter exercises with manometry-assisted biofeedback versus usual care 
using an educational pamphlet). Interventionists providing the anal sphincter exercise training with 
biofeedback have received standardized training and assessment. Symptom severity, diary, 
standardized anorectal manometry and health-related quality of life outcomes are assessed using 
validated instruments administered by researchers masked to randomized interventions. Cost 
effectiveness analyses will be performed using prospectively collected data on care costs and 
resource utilization. This article describes the rationale and design of this randomized trial, 
focusing on specific research concepts of interest to researchers in the field of female pelvic floor 
disorders and all other providers who care for patients with fecal incontinence.
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Introduction
Fecal incontinence (FI) is a common problem with a prevalence ranging from 2-15% in 
community settings and up to 19% in women presenting to specialty clinics.[1-3] The age-
adjusted prevalence of FI in non-institutionalized U.S. adults is 8.3% and consists of liquid 
stool in 6.2%, solid stool in 1.6% and mucus in 3.1%.[4]
Treatments for FI may be conservative including dietary manipulation, drug therapy, or 
behavioral treatments such as anal sphincter exercises/pelvic floor muscle training with or 
without biofeedback. [5] Surgical interventions include sphincter repair, rectocele repair, 
sacral neuromodulation, neosphincter, bulking injections or diversion.[5] Restoring normal 
bowel consistency is the first-line approach to therapy in patients with extremes of stool 
consistency (i.e. watery stools or hard and lumpy stools). This is usually accomplished using 
anti-diarrheal medications for patients with loose stools and laxatives or enemas for patients 
with constipation or incomplete emptying of the rectum. Since a significant proportion of 
women with FI will complain of leaking only with loose stool, an anti-diarrhea medication 
such as loperamide is often used as a first-line treatment. However, clinical evidence 
suggests that loperamide may have properties that could improve FI in patients with normal 
stool consistency.[6] A second conservative approach to treatment of women with FI is using 
anal sphincter exercises (pelvic floor muscle training) that may or may not include 
biofeedback assistance. Biofeedback therapy is often combined with additional behavioral 
interventions, such as bowel control strategies with sensory components. Multiple 
uncontrolled studies have suggested a benefit of behavioral interventions that include anal 
sphincter exercises with biofeedback for mixed liquid and solid stool consistency types of 
FI.[7]
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Since medical and behavioral approaches are often recommended as first-line treatments, [7] 
there is clinical value in determining the efficacy of these two conservative treatment options 
compared to placebo and basic educational information that are considered to be usual care 
for FI. Additionally, it is important to know if combined therapy offers any benefit over 
loperamide or anal sphincter exercises alone. The primary aims of the Controlling Anal 
incontinence by Performing Anal Exercises with Biofeedback or Loperamide (CAPABLe) 
trial are to compare the change from baseline in patient-reported scores of FI severity using 
the St. Marks (Vaizey) Score [8] at 24 weeks after treatment initiation among: 1) women 
randomized to loperamide versus oral placebo for the treatment of FI; 2) women randomized 
to anal sphincter exercises with biofeedback versus women randomized to usual care using a 
standardized educational pamphlet; and 3) women receiving the 2 active treatments together 
versus either active treatment alone. The purpose of this article is to describe the rationale 
and design of this randomized trial, focusing on specific research concepts of interest to 
researchers caring for women with FI, and to inform investigators designing randomized 
trials that combine medical interventions with standardized methods of behavioral 
interventions.
Methods
The Pelvic Floor Disorders Network (PFDN) is a clinical trials network composed of eight 
geographically diverse clinical centers in the United States, a Data Coordinating Center 
(DCC), and a Eunice Kennedy Shriver National Institute of Child Health and Human 
Development NICHD representative. The primary goal of the PFDN is to improve the level 
of knowledge about pelvic floor disorders and their treatments including pelvic organ 
prolapse, urinary incontinence and FI in women.
Rationale for using a factorial design
The value of using a factorial design for the CAPABLe study is that it allows a comparison 
of two first-line treatment options to placebo/usual care in a single population, thereby 
improving efficiency, reducing trial cost and allowing a comparison of combination therapy 
compared to single therapy for FI in women. A factorial design is particularly valuable in 
evaluating a combination of interventions that have separate mechanisms of action. Our 
study design directly compares anal sphincter exercises with biofeedback versus usual care 
and drug therapy with loperamide versus placebo, as well as comparing both treatments 
together compared with either alone.
Anal sphincter exercises with biofeedback and drug therapy for FI have different 
mechanisms of action that culminate in improving sphincter strength and anorectal 
sensation. The most well accepted properties of loperamide are that it affects gastrointestinal 
smooth muscle by inhibiting intestinal peristalsis [9-11] increasing oral-cecal transit time 
[12] and increasing the mucosal exposure to intestinal effluent and decreasing stool weight.
[13] Less known properties of loperamide are that it increases sensitivity of the recto-anal 
inhibitory reflex, [12] increases rectal perception and first incontinence volume [14] and 
increases anal sphincter squeeze duration.[14] These properties, along with decreasing fecal 
urgency, [14] promote quicker restroom-seeking behavior. Combined, this may serve as a 
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barrier to stool leakage, and to reduce the volume of stool in the rectum.[14] Anal sphincter 
exercises with biofeedback increase the squeeze strength of the anal sphincter through 
strength training, and when combined with sensory training, may reduce sensory thresholds 
for patients with rectal hyposensitivity leading to passive fecal incontinence, and increase 
sensory thresholds for urgency in patients with urge-related fecal incontinence 
(hypersensitivity).[6]
Design overview
The CAPABLe study design is shown in Figure 1. Eligible participants are randomized to 
one of four groups in a two-by-two factorial design: 1) usual care with oral placebo, 2) oral 
loperamide at a minimum dose of 2 mg taken orally every other day to a maximum of 8 mg 
daily with usual care, 3) anal sphincter exercise training with anorectal manometry-assisted 
biofeedback with usual care plus oral placebo and 4) combination oral loperamide with anal 
sphincter exercise training with manometry-assisted biofeedback with usual care. All 
participants receive an educational pamphlet developed by expert consensus which is 
publicly available from the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) (http://bowelcontrol.nih.gov/). This pamphlet includes basic information about FI 
and available treatments such as behavioral techniques and medications. For this trial, the 
pamphlet was modified by removing a single reference in the document to the drug 
loperamide. We felt that this basic information that is publicly available should be provided 
to all patients seeking care for FI. Enrollment began April, 2014 and recruitment is 
anticipated to continue through March 2016 (clinicaltrial.gov # NCT02008565).
Study Population
The study population consists of adult women with at least monthly FI over the last 3 
months that is bothersome enough to seek and desire treatment. Since FI may be a secondary 
symptom of colorectal malignancy, all women must have negative colon cancer screening 
based on one of the 2008 US Preventative Task Force recommended approaches. Women 
with predominant extremes of stool consistency on the Bristol Stool Form are excluded since 
patients with constipation are not candidates for potentially constipating agents such as 
loperamide and patients with chronic watery diarrhea may have a variety of causes for their 
diarrhea that need to be treated such as infectious etiologies.[15] A detailed list of the 
inclusion and exclusion criteria is in Table 1.
Randomization and Baseline Measures
Participants undergo a single randomization to one of the four treatment combinations. 
Randomization is a 0.5:1:1:1 allocation, to minimize the women who are randomized to no 
active therapy. Randomization is stratified by site using randomly permuted blocks; the sizes 
of the blocks are known only to the DCC.
After all screening assessments and consent are completed, the coordinator randomizes the 
participant at the baseline visit. Randomization is accomplished through the web-based data 
management system that assigns a randomization number that links to the biofeedback/usual 
care intervention assignment and loperamide/placebo treatment assignment. Women 
randomized to usual care undergo anal manometry measurements at baseline, 12 and 24 
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weeks. Women randomized to the anal manometry plus anal sphincter exercises with 
biofeedback intervention receive intervention at the baseline visit (following randomization) 
as well as at, 2, 4, 6, 9, 12 and 24 weeks. The loperamide/placebo is stored in and dispensed 
from the investigational pharmacy at each clinical site.
Masking
Table 2 demonstrates a summary of masking for the trial. For the anal sphincter exercises 
with biofeedback/usual care intervention, the physician, telephone interviewers, and the 
outcome evaluators are masked to the treatment assignment for the entire study duration. 
Behavioral interventionists are not masked to the anal sphincter exercises with biofeedback/
usual care assignments, but are masked to the loperamide/placebo assignment. For the 
loperamide/placebo intervention, the physician, participant, study coordinator(s) and 
telephone interviewers are masked to the assignment for the duration of the study, and only 
the research pharmacist is unmasked. A placebo tablet was manufactured to match the 
loperamide tablet as closely as possible in appearance and weight. Loperamide and placebo 
tablets are over-encapsulation by standard DB Capsules (Capsugel, Greenwood, SC) which 
are backfilled with a standard inert excipient (Avicel). Overencapsulation, bottling and 
labeling were done by a qualified contract manufacturing organization and drug supply 
provided to each site by the DCC. A two-part label was used such that an unmasked portion 
of the label can be removed and retained by the site pharmacist, and a masked label will 
remain on the bottle for distribution to the participant.
The protocol allows for dose adjustment during the trial ranging from 2 mg loperamide/
placebo (one capsule) orally every other day to a max of 8 mg loperamide/placebo (4 
capsules) daily. Dose adjustments are not performed by staff that collects outcome data since 
dose escalation or reduction may lead to unmasking; it was hypothesized that more placebo 
participants may dose escalate and more loperamide participants may dose reduce. 
Investigators felt it was important to allow for dose ranging due to efficacy and side-effects 
rather than limit participants to one or two escalation options. This allows for more accurate 
determination of an appropriate dose of loperamide for patients with FI. To accommodate 
this dose adjustment and minimize the possibility of the coordinator influencing dose, 
adjustments are standardized using a dose escalation/reduction matrix driven by the 
participant's rating of global symptom control and tolerability; this matrix is outlined in 
Table 3.
Medical Intervention with Loperamide versus Placebo
Participants randomized to the loperamide treatment group begin with 2 mg of loperamide 
per day. The FDA approved initial dose in adults with acute or chronic diarrhea is 4 mg (two 
capsules) followed by 2 mg (one capsule) after each unformed stool until diarrhea is 
controlled, after which, the dosage should be titrated to meet individual requirements, up to 
8 mg/day. For this study, participants are seen in person at their first treatment visit, 12 
weeks, and 24 weeks. Study coordinators also call the participants at the 2, 6, 16 and 20 
week intervals to administer global instruments to assess efficacy and tolerability of 
loperamide/placebo and manage dose adjustments accordingly. For evaluation of patient 
perceived efficacy, the Patient Global Symptom Control rating scale (PGSC) is used.[20] 
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Dose escalation is based exclusively on the result of the PGSC as shown in the Table 3, 
ranging from 1 (strongly disagree) to 5 (strongly agree). The participant is instructed to 
either maintain the current drug/dose if PGSC is 4 or 5 (agree/strongly agree that their 
treatment is giving adequate control of stool leakage), or dose escalate if PGSC is 1-3 
(disagree/strongly disagree that their treatment is giving adequate control) in the absence of 
bothersome side effects. Participants who report inadequate control of stool leakage on the 
PGSC are instructed to increase the daily dose of study medication by one capsule (2 mg 
loperamide or placebo) up to a maximum of 4 capsules (8 mg loperamide or placebo) per 
day. Participants are not required to take the entire daily dose at one time.
Bothersome side effects are monitored using a patient global tolerability scale (PGTS) which 
is modified from the PGSC.[20] Dose reduction is based on the participants' responses to the 
PGTS. The participant is instructed to reduce the current drug/dose if PGTS is 4 or 5 (agree/
strongly agree that the treatment is giving them bothersome side effects) as shown in the 
Table 3. Participants who report bothersome side effects of the medication are instructed to 
decrease the daily dose of study medication by one capsule to a minimum of one capsule (2 
mg loperamide or placebo) every other day. They are instructed to discontinue the study 
medication if they have a PGSC score of 1-3 (inadequate control of stool leakage) combined 
with a PGTS score of 4-5 (bothersome side effects). If bothersome side effects are reported 
at any time during the study, the participant is instructed to contact the clinical site and the 
site investigators may choose to discontinue or temporarily hold the study drug. In addition, 
dose reduction or medication discontinuation can occur at any time if a patient reports 
bothersome side effects.
Manometric Biofeedback Intervention versus Usual Care Alone
To address the limitations of most FI biofeedback intervention studies, investigators for this 
study developed 3 separate anal sphincter exercises with biofeedback sub-protocols: (1) 
strength training with home anal sphincter exercises, (2) sensory training for hyposensitive 
rectal distention, and (3) sensory training for urge-resistance rectal distention. Anorectal 
manometry (ARM) data were also standardized for this trial, and include measurements of 
strength, squeeze duration, and sensation. All participants have ARM performed at baseline, 
12 weeks, and 24 weeks. Among participants randomized to anal sphincter exercises with 
biofeedback, the ARM data are key measures for determining which of the sensory sub-
protocols to use along when combined with data from the patient-reported bowel diaries.
As provider experience is a major factor in performing anal sphincter exercises with 
biofeedback for FI, all study interventionists participating in the CAPABLe trial were 
required to review standardized online content, undergo hands-on training conducted with 
live models, and assessment by experienced providers trained using protocol-specific 
performance checklists. All interventionists were required to review online learning modules 
including instructional videos prior to attending the training sessions. Training included e-
learning content provided using slides, problem-oriented patient case discussions, and 
hands-on practice with live models. Each interventionist completed a 75 minute certification 
exam in the conduct of patient visits that included performing ARM diagnostic testing, 
manometric biofeedback with strength and sensory training and education on when to use 
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each sensory protocol. Trained interventionists include certified registered nurse 
practitioners, physician assistants and physical therapists. A minimum of two certified 
interventionists are available at each clinical site.
Subjects randomized to the anal sphincter exercises with biofeedback receive a structured 
individualized program during the first 12-weeks of the 24-week study including visits at 
baseline, 2, 4, 6, 9, and 12 weeks for a total of 6 biofeedback intervention visits. Diagnostic 
ARM evaluation is performed at each visit in order to guide the manometric biofeedback 
protocols and home anal sphincter exercises. All participants receive the strength training 
sub-protocol focusing on correct anal sphincter muscle isolation, anal sphincter contraction 
strength, and the duration of the contraction beginning at the first visit and continuing on 
subsequent visits as needed. The visits at, 2, 4, 6 and 9 weeks include a sensory protocol for 
participants who have partially lost the ability to detect the presence of stool in the rectum 
(called hyposensitivity) or a urge resistance protocol for those participants who experience 
strong sensations of urgency to defecate which are difficult to suppress (called 
hypersensitivity). At each visit, interventionists provide feedback using standardized 
handouts given that reinforce these techniques for home use. A manual of procedures 
describes guidelines in an algorithm approach to determine the correct sensory sub-protocol 
to use based on pre-determined criteria. We collaborated with the device manufacturer to 
develop on-screen prompts to guide the interventionists through these protocols. To help 
ensure adherence with this standardized regimen and treatment fidelity, audiotapes are 
obtained from select biofeedback sessions and members of the study team audit the tapes 
using standardized procedure checklists.
The software and catheter from the mcompass (Medspira, Minneapolis, MN) manometry 
device was redesigned specifically for this protocol. Building on existing software available 
for ARM, the research team partnered with staff from Medspira to create novel biofeedback 
software specifically tailored for the 3 biofeedback subprotocols in the trial. The mcompass 
system uses a tablet computer which wirelessly connects to the catheter. This system allows 
for equipment mobility and visual feedback to the participant for the strength and sensory 
training. The system's manometric catheter simultaneously measures pressures in the rectum 
and the anal canal to help participants isolate sphincter contractions while avoiding 
inappropriate contractions of abdominal wall muscles during strength training. The catheter 
contains a balloon that is positioned in the rectum and used to simulate rectal filling for the 
sensory protocols. All participants randomized to the anal sphincter exercises with 
biofeedback protocol are also prescribed a home exercise program based on their individual 
performance during the intervention visits. Participants record their home exercises in an 
exercise record and complete a seven-day bowel diary before the next anal sphincter exercise 
with biofeedback visit.
Subjects randomized to usual care are scheduled for visits with the interventionist at 
baseline, 12, and 24 weeks. ARM data are collected at these visits. The usual care subjects 
complete a 7-day bowel diary prior to these visits. At the baseline visit, the interventionists 
give the same structured education using the NIDDK bowel control handout that the anal 
sphincter exercises with biofeedback group receives.
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Data Collection and Follow up
A timeline of visits, events and data collection is listed in Table 4. After initial screening, 
eligible patients will be given a 7-day bowel diary and receive a Quality of Life (QOL) 
telephone interview. Randomization, review of bowel diary, and baseline ARM are 
performed at the baseline visit scheduled 2 to 4 weeks after the screening visit.
We attempted, when possible, to keep the study visits similar between groups. However, the 
group randomized to receive anal sphincter exercises with biofeedback has more 
intervention visits by the nature of the treatment. Participants randomized to usual care have 
in-person visits at baseline, 12 and 24 weeks. Conversely, those randomized to anal 
sphincter exercises with biofeedback have in-person visits at baseline, 2, 4, 6, 9, 12 and 24 
weeks. In our judgment, if we had kept the number of visits the same between the anal 
sphincter exercise with biofeedback group and the usual care group, this would have been 
perceived as artificial and burdensome to the usual care participants and may have 
influenced patient retention in the trial. A supply of study drug (loperamide) or placebo is 
dispensed at the baseline and 12 week visits. At 12 and 24 weeks, the participants are asked 
to bring their recently completed bowel diary to the clinic, to complete QOL interviews by 
telephone, and to undergo repeat ARM evaluation. Participants receive a telephone call from 
the research coordinator at weeks 2, 6, 16 and 20 to assess updates in medical history, 
medications, efficacy and tolerability of medications. Adverse events are collected on all 
participants at the 2, 6, 12, 16, 20, and 24 week calls or visits and at any time in between 
when self-reported bothersome symptoms are noted.
Participants in the anal sphincter exercises with biofeedback group are instructed to record in 
a diary the use of exercises at home. Compliance with loperamide/placebo is monitored 
using pill counts, a single question provider-reported adherence [23], and the modified 
Medication Adherence Self-Report Inventory (MASRI) [24] at the 12 and 24 week in-person 
visits. These three methods of “triangulation” are consistent with recommendations by 
Osterberg to use several methods in order to improve accuracy in assessing medication 
adherence.[25] Cost data and resource utilization are collected at the screening visit and at 
the 12 and 24 week visits. The primary outcome is assessed at the 24 week in-person visit by 
a masked coordinator. At this final visit, participants are asked if they know whether they 
received loperamide or placebo (i.e., whether they became unmasked).
Considerations in the selection of Primary Outcome
To meet recommendations of the NIH consensus statement and the Cochrane review, the 
protocol committee focused on using a primary outcome measure that could incorporate the 
patient perspective as well as FI frequency, severity, bother, fecal urgency and patient desire 
for treatment. Furthermore, the team also desired an instrument that had published evidence 
supporting its validity and data to guide the interpretation and clinical relevance of 
improvement in scores from the patient perspective. The protocol committee considered a 
variety of patient-centered outcome measures including severity scales, FI episodes, quality 
of life scales, global satisfaction scales, overall treatment satisfaction as well as using 
multiple primary endpoints. Unfortunately, no single primary outcome available for trials in 
FI that is broadly accepted was available. A variety of measures that more or less met 
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recommended requirements were reviewed, and the committee elected to use change from 
baseline to 24 weeks in the St Marks (Vaizey) FI severity scale as the primary outcome 
because the scale meets as many of the desired attributes as possible while maintaining 
participant acceptability. Data exist that correlate improvement in the frequency of FI 
episodes with improvement in the St. Marks (Vaizey) Score (r = 0.79, P<.001)[8], as well as 
moderate correlation with changes in maximum incremental squeeze pressure (r = -0.30, P < 
0.05).[26]
The St. Marks Score is also proved responsive to change. When assessing the correlation 
between the St. Marks Score and global impression of improvement after treatment, data 
demonstrate that average St. Marks Score severity scores are 1 point lower than baseline for 
patients who rate their situation as “worse or equal”, 4 points lower for patients who 
reported their situation to be “better”, and 9 points lower in patients who rate their situation 
“much better” (P < .05). This also supports the assertion that the St. Marks Score is 
consistent with patients' subjective perception of relief from FI.[26] For all of these reasons, 
the team felt that the St. Marks Score is the best existing measure that captures a meaningful 
outcome of FI treatment.
Secondary outcome measures
The secondary outcome measures listed in Table 5 are alternative measures of treatment 
efficacy. The key secondary outcomes are the frequency of FI episodes on a 7-day bowel 
diary, and validated quality of life measures, which are measured at baseline, 12 weeks, and 
24 weeks in all treatment groups. Additional secondary outcome measures are tallies of 
adverse events and estimates of the cost of delivering the interventions. Secondary safety 
outcomes include monitoring of adverse events. Comparisons of adverse events and serious 
adverse events between treatment groups will be reported at the end of the study. All adverse 
events and serious adverse events reported by participants are compared between treatment 
groups on a quarterly basis and reviewed by the Data Safety Monitoring Board. Possible 
adverse events include abdominal distension, abdominal pain or discomfort, allergic 
reactions, constipation, nausea, vomiting, tiredness, dizziness, and drowsiness. Bothersome 
adverse events will be classified using the PGTS. Study drug dose reduction will be based 
exclusively on the result of the PGTS.
Measures of compliance with study interventions
Adherence to taking the study medication, the exercise log, number of anal sphincter 
exercises and biofeedback visits completed, and audits of tape recordings to assess whether 
the interventionists adhered to the procedure manual are measures that address the degree of 
adherence with study interventions. The questionnaire to assess whether participants were 
unmasked to whether they received loperamide or placebo assesses the integrity of masking 
in the drug treatment arm.
Mediators of treatment effects
The ARM test at baseline, 12 and 24 weeks is a process measure that assesses whether the 
anal sphincter exercises and biofeedback are having the expected impact on anal canal 
squeeze pressure, rectal pressure during squeezing, and sensory thresholds for first sensation 
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and strong urge. These are hypothesized to mediate the impact of pelvic floor exercises and 
biofeedback on the St. Marks score of FI severity. The ARM test is performed at baseline, 
12, and 24 weeks. Socio-demographic variables measured at baseline will also be examined 
as possible moderators of treatment efficacy.
Sample size and Power
Table 6 describes the hypothesized value of the primary outcome in each of the treatment 
groups. A difference in change from baseline in St. Marks (Vaizey) score at 24 weeks of at 
least 5 is hypothesized between each of the groups assigned to receive a single active 
treatment and those randomized to usual care (placebo and educational pamphlet), and a 
modest negative interaction is assumed in the combined therapy arm (loperamide and anal 
sphincter exercise + biofeedback). This is consistent with the minimally important difference 
(MID) of -5 for the St. Marks (Vaizey) score derived using three different methods of 
detecting a clinically important difference.[27] In the study conducted by Bols et al., various 
methods were used to estimate the MID and the authors concluded that an MID of -5 
seemed preferable and yielded the lowest misclassification rate.[27] We also requested from 
Bols et al. a reanalysis of the MID of the St. Marks (Vaizey) score without the medication 
item in the questionnaire, and it appears that an MID of -5 is still appropriate for the 
modified St. Marks (Vaizey) score without medication.
Randomization will be unequal, with fewer patients randomized to the combination of 
placebo drug and usual care (0.5:1:1:1 allocation). Power calculations were based on the 
hypothesized changes from baseline in St. Marks (Vaizey) score at 24 weeks shown in Table 
6. If we assume a follow up rate of 100% at 24 weeks, then a sample size of 245, with 35 
participants in the placebo/usual care group and 70 in each of the other three groups, will 
provide 90% power to detect a difference in each treatment arm (loperamide vs. placebo 
averaged over the two exercise treatments and exercise + biofeedback vs. usual care 
averaged over the two drug treatments) at a 0.025 level of significance. It will also provide 
80% power to detect a difference in drug alone or exercise alone vs. the placebo/usual care 
combination, and 55% power to detect a difference in combined drug and exercise vs. either 
intervention alone, at a 0.05 level of significance. The power to detect an interaction that is 
significant at the 0.05 or 0.10 levels will be approximately 14% and 23%, respectively. 
Despite having only 55% power, we chose to include the third aim as primary rather than 
secondary, because we think it is important to compare combination therapy to each 
treatment alone. It may be particularly important if the magnitude of the interaction between 
the treatment arms is greater than we anticipate, in which case our power to detect the 
differences would also be higher than our estimates indicate. If we assume a conservative 
follow up rate of 85% at 24 weeks, and we use analysis methods that are consistent with an 
assumption that missing outcomes will be missing at random, then power calculations yield 
a sample size estimate of 294 patients (42 in the usual care (educational pamphlet)/placebo 
group and 84 in each of the other treatment combinations) to obtain the power levels 
described above.
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The primary outcome, change from baseline in St. Marks (Vaizey) Score at 24 weeks, will 
be compared among treatment groups using linear regression. Because the St. Marks 
(Vaizey) score is assessed at both 12 and 24 weeks, the primary analysis will be based on a 
longitudinal model, with changes from baseline in St. Marks (Vaizey) score at both 12 and 
24 weeks as the dependent variable, and the independent variables including treatment 
assignment (both drug and exercise), interaction between drug and exercise treatment 
assignments, week (12 or 24), 2- and 3-way interactions between week and treatment 
assignments, Rome III irritable bowel syndrome (IBS) clinical trial status, interaction 
between Rome III IBS clinical trial status and treatment, and clinical site. If the interactions 
between treatment arms and/or between treatment and Rome III IBS status are not 
statistically significant, then the statistical test comparing the treatment groups will be 
averaged over the other variable involved in the interaction. If there is a statistically 
significant interaction, then the treatment groups will be compared within each level of the 
other variable involved in the interaction. The interactions between time and treatment arms 
will allow for statistical tests to compare the treatments at the 24 week time point for the 
primary outcome, since the model will include change from baseline at both 12 and 24 
weeks. Patients with IBS may be included in the trial as IBS remains an important risk factor 
for fecal incontinence. However, the analysis will control for this using the interactions 
described. Under the assumption that any missing outcome data will be missing at random 
(thus, missing St. Marks (Vaizey) scores at 24 weeks may be related to both 12-week 
outcomes and covariates), this model will produce more accurate estimates in the presence 
of missing data than one that models only outcomes at 24 weeks. The model will account for 
the dependence between repeated measurements on the same subject. Two-sided tests of the 
effect of drug treatment assignment (loperamide vs. placebo) and exercise treatment 
assignment (anal sphincter exercises with biofeedback vs. usual care (educational 
pamphlet)) on change from baseline in St. Marks (Vaizey) Score at 24 weeks will be 
performed at a type I error level of 0.025. The same model will be used to test whether there 
is a difference in combination treatment compared to loperamide and combination treatment 
compared to anal sphincter exercises with biofeedback in change from baseline in St. Marks 
(Vaizey) Score at 24 weeks with type I error of 0.05. We will also test for differences in the 
change in score over time among the 4 individual treatment groups. Missing data 
mechanisms will be explored, and sensitivity analyses will be conducted to assess the 
robustness of the previously described analyses. Methods employed for sensitivity analyses 
may include multiple imputation or inverse probability weighting methodology.[28, 29]
We will evaluate secondary outcomes evaluated at 12 and 24 weeks, including efficacy 
outcomes, additional treatments for FI, adherence to study treatment and adverse events, 
comparing loperamide vs. placebo, anal sphincter exercises with biofeedback vs. usual care 
(educational pamphlet), and combination therapy vs. each individual treatment. For 
categorical outcomes, generalized linear modeling will be used instead of linear regression. 
We will evaluate changes from baseline to 12 and 24 weeks in condition-specific and 
generalized quality of life, sexual function, and adaptation comparing loperamide vs. 
placebo, and anal sphincter exercises with biofeedback vs. usual care (educational 
pamphlet), and combination therapy versus each individual treatment. Patient satisfaction 
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with treatment modality at 12 and 24 weeks, defined as “much better” or “very much better” 
on the PGI-I, will be assessed using generalized linear modeling based on the predictors 
described in the model for the primary aims.
We will conduct exploratory analyses to evaluate whether a number of factors act as 
confounders (mediators) of any treatment effects for either drug/placebo or biofeedback/
usual care treatments, whether these factors potentially act as effect modifiers for these 
treatments, or whether the factors act as independent predictors of changes in FI. This 
analysis will use similar models to those described for the primary outcome to model change 
from baseline to 12 and 24 weeks in St. Marks (Vaizey) Score as a function of both 
categorical measures (presence of IBS, stool consistency, a three-level measure of treatment 
adherence for both treatment modalities, and adverse events) and continuous measures 
(bowel diary measures, constipation symptoms, digital rectal tone, anal manometry 
measures, and dietary fiber intake). To evaluate whether the factor acts as a confounder 
(mediator) of the treatment effect, the model will include the same terms as the primary 
outcome models with the factor added to determine whether the addition of the factor results 
in a change in the estimated treatment effect. To assess whether each factor acts as a 
treatment effect modifier, terms for the factor, the factor by treatment interaction and for the 
treatment by time by factor interaction will be added to the model.
A decision-analytic model will be constructed to evaluate the cost-effectiveness of 
loperamide, anal sphincter exercises with biofeedback, and combined therapy. The analysis 
will be conducted from a patient and societal perspective and the model will include costs 
for the intervention, as well as for the management of adverse events, productivity loss and 
use of FI products (e.g., pad use) during the six-month period following initiation of 
treatment. The intervention cost will be estimated based on the amount of medication and 
number of exercise/biofeedback sessions that the participants used/attended during the trial. 
The probability of adverse events, amount of productivity loss, and FI product use will also 
be based on results from the CAPABLe trial. Effectiveness will be measured using quality 
adjusted life years (QALY). A validated algorithm developed by Brazier and Roberts (2002) 
will be used to generate a preference-based index score and hence QALYs based on patients' 
responses to the SF-12 questionnaire collected during the CAPABLe trial.[30] Compared to 
other utility elicitation methods (e.g., standard gamble, time trade-off), this approach helps 
minimize subject burden. Cost-effectiveness will be assessed by the incremental cost 
effectiveness ratio (ICER), which reflects the incremental cost associated with each 
additional QALY. In addition, we will perform sensitivity analyses to assess how the cost-
effectiveness of each intervention may change when varying the value of key input 
parameters in the model.
Validity of anal manometry will be assessed by measuring the association between 
manometry measures and digital squeeze strength, incontinence severity (St. Marks Score), 
global impression of improvement, and impact on quality of life as measured by the CRADI 
subscale on the PFDI, CRAIQ subscale on the PFIQ, Modified Manchester, and FI 
adaptation index. Chi-square tests will be used to compare drug treatment groups with 
respect to the percent of participants/coordinators who responded that they thought the 
participant was assigned the active or placebo treatment or did not know which treatment 
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had been assigned. Confidence intervals for the number of unmasked participants/
coordinators in each treatment group will be estimated. Open-ended responses regarding the 
reason for thinking the patient was in either the active or placebo group will be categorized 
and reported descriptively.
Discussion
This large multisite study tests two conservative treatments of FI, the antidiarrheal 
medication loperamide and anal sphincter exercises with biofeedback. These two treatments 
are recommended by clinical practice guidelines as first-line treatments for FI, but the 
evidence for their efficacy is insufficient. Studies supporting the use of loperamide for FI 
were small, uncontrolled studies published more than 10 years ago, and limited to patients 
with diarrhea-associated FI.[16] Most studies of pelvic floor biofeedback for the treatment 
of FI were single-site studies and have yielded inconsistent results, raising concerns that the 
outcomes are highly dependent on the skills and experience of the interventionist.[21] Thus, 
a well-controlled, multisite study to assess the efficacy of each of these treatment approaches 
is needed. The CAPABLe trial is the first adequately powered multi-center clinical trial to 
evaluate both of these primary interventions for FI, and the results will fill important voids in 
our knowledge of the treatment of this troubling condition.
A strength of this study is that these two treatments are being tested simultaneously in a 
factorial design; each active treatment, loperamide and biofeedback, is paired with an 
appropriate control, with loperamide being compared to placebo tablets and biofeedback 
compared to a standard-care educational intervention. This is an efficient study design that 
makes it possible to evaluate efficacy of these two independent treatments simultaneously 
without the cost and effort that would be required for two independent, parallel group 
studies. Another advantage of this design is that it will allow us to test whether combining 
the two active treatments is more effective than either treatment used alone. However, our 
target sample size provides only 55% power to detect the hypothesized 3-point difference in 
change from baseline in St. Marks (Vaizey) score at 24 weeks between those randomized to 
both versus only one active treatment.
Loperamide is a logical choice for first-line treatment of FI because (a) diarrhea is 
consistently found to be the strongest risk factor for FI in population-based surveys [1, 4] 
and (b) incontinence for liquid stools is 4 times more common than incontinence for solid 
stools.[4] However, constipation is an adverse event that affects an estimated 2.4% of 
patients who are treated with loperamide for diarrhea and/or diarrhea related FI,[31] and 
currently loperamide is only approved by the FDA for the treatment of diarrhea. In this 
study, we decided not to limit enrollment to patients with diarrhea-associated FI but to 
include patients with normal Bristol Stool consistency ratings of 2-6[15]. We believe the 
decision to include patients with a range of stool consistency provides the best opportunity 
to assess the generalizability of loperamide as a first-line treatment for FI. We will be able to 
investigate whether Bristol Stool Scale scores at enrollment predict the response to 
loperamide treatment in secondary analyses.
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It can be challenging to recruit patients to participate in a study of the efficacy of drugs that 
are already available to the patient through prescription or as an over-the-counter 
medication; they may have a negative expectation of benefit based on their prior experience 
with the drug, or they may opt to try the drug without the burden of participating in the trial. 
The use of a factorial design may mitigate this problem because each patient is offered two 
treatments and has the possibility of experiencing two effective treatments in combination. 
In this study, we will exclude participants who have taken loperamide in the previous 30 
days or who have failed a treatment trial of loperamide or diphenoxylate within the last 3 
months. However, we will not eliminate all patients who have taken loperamide in the past 
because patients who have never taken this popular treatment for FI would likely represent a 
biased subset of patients who have milder symptoms of FI and/or who have constipation-
related FI.
Subjects vary in their response to any investigational drug and their tolerance for its side-
effects. Investigators frequently want to take this variability into account by titrating the dose 
of the investigational drug treatment (and the placebo) for each subject; however drug 
titration creates opportunities for (1) unmasking the trial and (2) introducing experimenter 
bias. In this study, we eliminate these threats by titrating the drug dose based on subject-
ratings of improvement in FI frequency and subject-ratings of side-effects in a standardized 
fashion.
One challenge in designing this study was deciding on what the control group would be to 
compare to the anal sphincter exercises with biofeedback group. We decided to compare 6 
sessions of anal sphincter exercises with biofeedback to a standard educational intervention 
in the form of an educational brochure delivered only at the initial visit. It could be argued 
that these two treatments are not balanced for nonspecific treatment components such as 
expectation of benefit or contact time with an interventionist. We decided to use a standard 
care educational control for the following reasons: (1) Biofeedback training is a complex, 
multicomponent treatment, and it remains difficult to identify the key mechanism(s) 
mediating treatment efficacy. Parallel group treatment trials often aim to isolate the key 
mediator of treatment efficacy, but that is not possible with biofeedback. (2) The use of a 
complex control condition such as 6 sessions of anal sphincter exercises taught without 
biofeedback devices would introduce additional non-specific treatment components, such as 
targeted counseling from the interventionist that would make it difficult to interpret the 
loperamide vs. placebo arm of the study in the context of this factorial design. For these 
reasons, we concluded that we should first establish that anal sphincter exercises with 
biofeedback are superior to minimum standard care (e.g. education) in an adequately 
controlled multisite study.
Two challenges in evaluating behavioral interventions such as biofeedback are (1) that the 
intervention protocol is not standardized so there are variations in how it is implemented in 
different clinics, and (2) the outcomes seem to depend on the skill and experience of the 
interventionists. To address the first problem, a group of experts on the biofeedback 
treatment of FI worked to disaggregate biofeedback training for FI into three key 
procedures: strength training, sensory discrimination training to improve the detection of 
rectal filling, and desensitization to the sensation of urgency to defecate. We then 
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collaborated with a device manufacturer to develop separate software programs for each of 
these biofeedback procedures. To address the second problem, the protocol was standardized 
in the manual of operations, required in person training and certification, and monitored 
through audiotapes.
The design, interventions and outcome measures of the CAPABLe trial have been carefully 
considered in order to provide valid, reliable estimates of the efficacy, safety and cost-
effectiveness of two commonly used primary conservative therapies for women with FI with 
a focus on patient-centered outcomes. This study will provide important foundational 
evidence for the treatment of this common and burdensome condition.
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Table 1
Protocol Inclusion and Exclusion Criteria
Inclusion criteria:
1 Age ≥18 years
2 Fecal incontinence defined as any uncontrolled loss of liquid or solid fecal material that occurs at least monthly over the last 3 
months that is bothersome enough to desire treatment
3 If a patient is 50-75 years old they should have current negative colon cancer screening based on the US Preventative Task Force 
recommendation (2008) that includes either:
a. Annual screening with high-sensitivity fecal occult blood testing or
b. Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing every 3 years or
c. Screening colonoscopy every 10 years
Patients who are ≥76 years old do not need routine colon cancer screening since the likelihood that detection and early 
intervention will yield a mortality benefit that declines after age 75 because of the long average time between 
adenoma development and cancer diagnosis. Patients 50-75 years old without a current negative colon cancer 
screening may elect to undergo one of these screening options and if results are normal, they may continue to screen 
for eligibility in the trial.
Exclusion criteria:
1 Stool consistency over the last 3 months that includes items 1 or 7 based on the Bristol Stool form scale
2 Current bloody diarrhea (loose, watery stools 3 or more times a day with blood)
3 Current or past diagnosis of colorectal or anal malignancy
4 Diagnosis of inflammatory bowel disease
5 Current or history of rectovaginal fistula or cloacal defect
6 Rectal prolapse (mucosal or full thickness)
7 Prior removal or diversion of any portion of colon or rectum
8 Prior pelvic floor or abdominal radiation
9 Refusal or inability to provide written consent
10 Inability to conduct telephone interviews conducted in English or Spanish
11 Fecal impaction by rectal and abdominal exam
12 Untreated pelvic organ prolapse beyond the hymen; Patients with prolapse beyond the hymen who are currently using a pessary 
are eligible
13 Incontinence only to flatus
14 Has taken any loperamide (Imodium®) or diphenoxylate plus atropine (Lomotil®) in the last 30 days
15 Previously received and failed treatment of fecal incontinence using loperamide (Imodium®) or diphenoxylate plus atropine 
(Lomotil®) over the last 3 months
16 Current supervised anal sphincter exercise/pelvic floor muscle training with biofeedback
17 Previously received and failed treatment of fecal incontinence using supervised anal sphincter exercise/pelvic floor muscle 
training with biofeedback
18 Previous allergy or intolerance to loperamide
19 Pregnant, nursing, or planning to become pregnant before the end of the study follow-up period.
20 Childbirth within the last 3 months
21 Neurological disorders known to affect continence, including spinal cord injury, advanced multiple sclerosis or Parkinson's 
disease and debilitating stroke
22 Known diagnosis of hepatic impairment
23 Chronic abdominal pain in the absence of diarrhea
24 Acquired Immunodeficiency Syndrome (AIDS)
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25 Currently taking anti-retroviral drugs


















Masked to Anal sphincter exercises with biofeedback/usual care Intervention
Participant Yes No
Study coordinator Yes Yes
• Primary outcome
• Most secondary outcomes
No
• Anal sphincter exercises withbiofeedback/usual care 
treatmentassignment
• Adverse events
• Medical follow up
• Adherence
• Productivity data collection
Telephone interviewer* Yes Yes





Telephone interviewer: individual from the Quality of Life Call Center
**
Evaluator: the individual(s) at the clinical sites performing outcome assessments
#
Interventionist: the individual(s) at the clinical sites providing the anal sphincter exercises with biofeedback/intervention and conducting rectal 
manometry measurements













Jelovsek et al. Page 26
Table 3
Dose Escalation/Change in Study Medication and Management of Adverse Events 
between Medication Steps, based on Efficacy and Tolerability
Efficacy
Yes (PGSC 4,5) No (PGSC 1-3)
Tolerability Yes (PGTS 1-3) No change in medication Dose escalate*
No (PGTS 4-5) Dose reduction** Patients are instructed to discontinue medication
*
Max dose of 4 capsules (8 mg loperamide or placebo) per day
**
Minimum dose of 1 capsule (2 mg loperamide or placebo) every other day
The Patient Global Symptom Control rating scale (PGSC)[20] is:
My current treatment is giving me adequate control of my stool leakage.
Disagree 1 2 3 4 5 Agree
Strongly Strongly
The Patient Global Tolerability rating Scale (PGTS) is:
My current medication is giving me bothersome side effects?
Disagree 1 2 3 4 5 Agree
Strongly Strongly
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Table 5
Secondary outcomes in CAPABLe
Medication and Medical History Review
Previous and interval treatment for pelvic floor disorders or bowel disorders
7-day bowel diary
Anal sphincter tone on physical examination using the Digital Rectal Examination Scoring System
Manometry measures including: distance (cm) of catheter insertion to locate high pressure zone (HPZ) of anal canal, resting anal canal 
pressures (mm of Hg) at 2 cm, 1 cm, and 0 cm insertion, resting rectal pressures (mm Hg) with anal sensor at 2 cm, 1 cm, and 0 cm insertion, 
maximum anal and rectal pressures during squeeze with the catheter at the HPZ, volume of air (mL) at first sensation for perception of rectal 
distention, volume of air (mL) at urge to defecate, maximum tolerable rectal volume of air (mL), volume of air (mL) at sensation of strong urge 
and rectal balloon pressure at sensation of strong urge
Dietary fiber intake using the Fruits/Vegetables/Fiber Screener questionnaire [36]
Pelvic Symptoms: Pelvic Floor Distress Inventory Short Form (PFDI-Short) including all subscales, Pelvic organ prolapse/urinary incontinence 
sexual function questionnaire – IUGA Revised (PISQ-IR) and an additional anal intercourse question Modified Manchester Health 
Questionnaire that includes the 4-item Fecal Incontinence Severity Index (FISI) [32, 38, 39]
Modified Patient Global Impression of Improvement (PGI-I) for bowel function, Adaptation using the Fecal Incontinence Adaptation Index, 
Defecatory symptoms as measured by Patient Assessment of Constipation Symptoms questionnaire (PAC-SYM) [41, 42]
Quality of life - Medical Outcome Study Short-Form-12 (SF-12) including all subscales, Pelvic Floor Impact Questionnaire Short Form 
including all subscales (PFIQ-Short), Body Image Scale [33, 38, 40]
Efficacy and Tolerability using the Patient Global Symptom Control rating scale (PGSC) and Patient Global Tolerability Scale (PGTS) modified 
from the PGSC [20]
Compliance with treatment using pill counts, a single question provider-reported adherence [23] and the modified Medication Adherence Self-
Report Inventory (MASRI) [24] Adverse events
Productivity loss including: days of missed work, missed household chores, caregiver costs, travel time, transportation costs, out of pocket 
appointment costs, incontinence products costs and laundry costs.
Rome III IBS criteria[37]
Bowel leakage as measured by the Accidental Bowel Leakage (ABLe) instrument
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Table 6
Hypothesized change from baseline in St. Marks (Vaizey) Score at 24 weeks in each 
treatment group
DRUG EXERCISE
Usual care (educational pamphlet) Anal Sphincter Exercise + Biofeedback
Placebo -2 -7
Loperamide -7 -10
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